Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

July 15, 2027

Study Completion Date

March 15, 2028

Conditions
AML, AdultMDS
Interventions
DRUG

Eganelisib

eganelisib will be administered as monotherapy

DRUG

Eganelisib in combination with cytarabine

eganelisib will be administered in combination with cytarabine

Trial Locations (13)

10003

RECRUITING

Hospital San Pedro de Alcántara, Cáceres

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10466

RECRUITING

Montefiore Medical Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

Ohio State University, Columbus

44106

RECRUITING

Cleveland Clinic, Cleveland

46026

RECRUITING

Hospital Universitari i Politècnic La Fe, Valencia

63110

RECRUITING

Washington University in St Louis, St Louis

77054

RECRUITING

MD Anderson Cancer Center, Houston

80045

RECRUITING

Anshutz Cancer Pavilion, Aurora

91010

RECRUITING

City of Hope, Duarte

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Stelexis BioSciences

INDUSTRY